Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
Martine Dehlinger-Kremer, Ph.D.
Advertisement
Martine Dehlinger-Kremer, Ph.D., brings 30+ years of experience in the research industry, with recognized expertise in global regulatory affairs, medical affairs, maternal–fetal medicine, and pediatric development. Driven by the goal of ensuring safe, effective treatments are accessible to every child, she is currently senior development strategy lead for pediatrics at UCB Biosciences, focusing on advancing innovative approaches to pediatric drug development.
Articles by Martine Dehlinger-Kremer, Ph.D.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
Rebuilding Clinical Data Workflows for the AI Era
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5